Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma
This is an open-label, randomized, phase II study to evaluate the clinical activity of pembrolizumab in combination with pazopanib compared to pazopanib monotherapy.
Soft Tissue Sarcoma
DRUG: pembrolizumab, pazopanib
Progression Free Survival (PFS), Progression Free Survival (PFS), 12 weeks
Progression Free Rate (PFR), Progression Free Rate (PFR), 12 weeks|Overall Response Rate (ORR), Overall Response Rate (ORR), 12 weeks|Overall Survival(OS), Overall Survival(OS), 4 months|Adverse Events(AE), Adverse Events(AE), 6 months
Pembrolizumab will be given for a maximum of 2 years i.e. a total of 35 cycles of pembrolizumab with the q3 week dosing. Participants who complete study intervention after 2 years of pembrolizumab can be treated with pazopanib monotherapy based on physician's judgement. The duration of optional pembrolizumab crossover treatment will be maximum of 2 years i.e. a total of 35 cycles of pembrolizumab for patients progressing on pazopanib.